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Abstract: Acute myeloid leukemia (AML) is a heterogeneous group of diseases characterized by
uncontrolled proliferation of hematopoietic stem cells in the bone marrow. Malignant cell growth
is characterized by disruption of normal intracellular signaling, caused by mutations or aberrant
external signaling. The phosphoinositide 3-kinase (PI3K)-Akt-mammalian target of rapamycin
(mTOR) pathway (PI3K-Akt-mTOR pathway) is among one of the intracellular pathways aberrantly
upregulated in cancers including AML. Activation of this pathway seems important in leukemogenesis,
and given the central role of this pathway in metabolism, the bioenergetics of AML cells may depend
on downstream signaling within this pathway. Furthermore, observations suggest that constitutive
activation of the PI3K-Akt-mTOR pathway differs between patients, and that increased activity
within this pathway is an adverse prognostic parameter in AML. Pharmacological targeting of the
PI3K-Akt-mTOR pathway with specific inhibitors results in suppression of leukemic cell growth.
However, AML patients seem to differ regarding their susceptibility to various small-molecule
inhibitors, reflecting biological heterogeneity in the intracellular signaling status. These findings
should be further investigated in both preclinical and clinical settings, along with the potential use of
this pathway as a prognostic biomarker, both in patients receiving intensive curative AML treatment
and in elderly/unfit receiving AML-stabilizing treatment.
Keywords: Akt; AML; chemotherapy; metabolism; mTOR; PI3K; signaling
1. Introduction
1.1. Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive malignancy characterized by rapid proliferation
of immature myeloid leukemia cells [1,2]. In most cases, this disease involves a bone marrow
malignancy, although malignant cells may also be detected in peripheral blood or as extramedullary
infiltration [1,3,4]. The acute promyelocytic leukemia (APL) variant of AML is characterized by specific
genetic abnormalities in the leukemic cells and severe coagulopathy, and treatment differs from that
of other types of AML [5–7]. In this review, we use the term AML to refer to non-APL variants of
the disease.
For a significant majority of patients, AML primarily affects the bone marrow, and by
definition, at least 20% of the nucleated bone marrow cells are immature or undifferentiated
leukemia blasts [2]. Based on etiology, AML could be classified as de novo, secondary, i.e.,
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after previously other hematological malignancies or after chemoradiotherapy for other malignant
diseases, or relapsed/refractory, after reoccurrence of the disease after treatment or lack of treatment
response [8]. Cytogenetic and molecular genetic aberrations in AML have additional diagnostic
and prognostic impacts [1,9]. Several strategies for subclassification, such as micro-RNA, epigenetic,
transcriptomic, metabolomic, and proteomic characterization, have been suggested, although are
currently not a part of routine handling of these patients [10–15]. Intensive chemotherapy is the only
treatment that can cure AML, and autologous or allogeneic stem cell transplantation can be a part
of this intensive treatment [3]. For patients who cannot tolerate intensive treatment, e.g., elderly
patients over 70–80 years of age, and patients with severe comorbidity, the most commonly used
antileukemic treatments have traditionally included demethylating agents such as azacitidine or
decitabine, and low-dose cytarabine [16–19], or more recently the inhibitor of the B-cell lymphoma-2
(BCL-2) protein, venetoclax [20,21].
1.2. Leukemic Stem Cells
A blockade of differentiation in AML results in the excess production of undifferentiated and
immature leukemic blasts, showing limited proliferative capacity and acquired critical genetic or
epigenetic alterations that disrupt important growth-regulatory pathways [22]. AML is expressed
as abnormal development in one of the major blood lineages; however, the blasts from patients are
heterogeneous with respect to the lineage antigens they express [23,24]. The hierarchical organization
within the leukemia clone is also reflected in its cellular heterogeneity, e.g., with respect to morphology,
cell surface markers or functional characteristics, and is similar to that of normal hematopoiesis [25].
AML was one of the first diseases for which the existence of a population of cancer stem cells was
suggested [26]. Consequently, human AML leukemic stem cells (LSCs) represent one of the most well
characterized populations of cancer stem cells [27]. These cells are generally defined by functional
assays, i.e., long-term culture or xenograft models, and these functionally defined stem cells can be
detected in different cell subsets, i.e., they differ in their expression of cell surface markers [28,29].
However, further characterization of the phenotype of LSCs has revealed several differences
between LSCs and normal hematopoietic stem cells (HSCs). Most leukemic cells in AML express
CD34, which is the normal surface marker for hematopoietic stem/progenitor cells (HSPCs) [30,31].
Within the total AML cell population, LSCs are always a minority, and patients can have AML stem
cells with CD34+38-, CD34+CD38+ and/or CD34- phenotypes [32,33]. However, for approximately
25% of AML patients, more than 90% of the total AML cell population is CD34- [32,34,35], and this
phenotype is associated with the nucleophosmin 1 (NPM1) mutation [33,34]. Finally, the Lin-CD34+
fraction of AML patients can be divided into two subpopulations based on AML stem cells. These two
populations are similar to normal lymphoid-primed multipotent progenitors (CD38-CD90-CD45RA+),
and granulocyte macrophage progenitors-like cell populations (CD38+CD123+CD45RA+) [35]. In most
patients, both populations coexist and possess LSC potential [35]; thus, there is also heterogeneity
within the LSC populations.
2. Malignant Cell Metabolism and Its Possible Clinical Importance in AML
2.1. Metabolism in Malignant Diseases
One of the hallmarks of cancer cells, as proposed by Hanahan and Weinberg in 2000, is their
altered metabolic state [36]. The last decades have increased our knowledge of how metabolism is
altered in cancer cells, this in concordance with mapping of activation of signal transduction pathways
regulating nutrient metabolism. Central for this research is the notion that metabolic pathways are
reprogrammed in cancer cells to divert nutrients towards anabolic processes for heightened growth
and proliferation. Normally, access to and subsequent utilization of nutrients is highly regulated by
physiological cellular signaling mechanisms, providing an important barrier to transformation [37].
Cancer cells can meet their own bioenergetic needs by altering their metabolism to promote growth,
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survival, proliferation, and long-term maintenance. In normal cells, mitochondria are the main
components in the generation and regulation of cellular bioenergetics and are responsible for the main
production of ATP by oxidative phosphorylation [37]. Cancer cells do not follow the normal pathway
for energy production, and this altered metabolism found in cancer cells includes a switch from
mitochondrial oxidative phosphorylation to provide an increased glucose uptake and fermentation of
glucose to lactate; this is observed even in the presence of both fully functioning mitochondria and
oxygen, and is referred to as the Warburg effect. Metabolism in cancer cells can be reprogrammed from
a homeostatic state, with high nutrient catabolism or storage, to an anabolic state where nutrients are
transformed into biomass [38].
Switch to aerobic glycolysis has the potential to provide tumor cells with a proliferative advantage,
and has thus increased the interest regarding investigation into the mechanisms by which this process is
triggered and regulated in order to determine the best means of exploiting this pathway for therapeutic
gain [39]. Consequently, given the importance of promoting nutrient uptake and utilization in
cell-building processes, it becomes clearer that cancer cells repeatedly select for mutations that increase
signal transmission through pathways that unite in a common set of metabolic processes.
2.2. Metabolism in AML
As for malignant cells in general, AML cells also have considerable alterations in their metabolic
features. Malignant cells often have a reprogrammed and upregulated metabolism with glucose
consumption for energy generation, use of glutamine for the refilling of the intermediates of the
tricarboxylic acid (TCA) cycle, and fatty acid synthesis for the building of cellular membranes [40],
and this has also been shown for AML cells [10,41,42]. AML cells can adapt to meet the increased
energy or substrate demand during stressful conditions in the bone marrow microenvironment.
However, while normal HSCs apply glycolysis mainly as a source for energy homeostasis, recent studies
show that LSCs are mainly dependent on oxidative phosphorylation for survival [43]. In newly
diagnosed patients, variable proportions of both high and low oxidative phosphorylation are found in
AML cells, whereas in post-chemotherapy patients, there is an excess of high oxidative phosphorylation
cells. This indicates that mitochondrial oxidative phosphorylation may be associated with AML
chemoresistance, and high oxidative phosphorylation signatures and metabolism are identified as
hallmarks of chemoresistance in vivo [43].
Of special interest in the setting of AML and metabolism, is the last decade’s discovery
that 10%–15% of AML patients have mutations in the genes isocitrate dehydrogenase (IDH)1 and
IDH2 [44]. The IDH proteins are critical for the TCA cycle, catalyzing the oxidative decarboxylation of
isocitrate to α-ketoglutarate. Mutations in the IDH genes lead to production of the oncometabolite
2-hydroxyglutarate. Hence, a specific metabolic profile associated with IDH mutations have been
identified, and serum levels of 2-hydroxyglutarate seems to have both potential diagnostic and
prognostic impact [45]. Taken together, these findings clearly highlight the importance of metabolic
deregulations in supporting leukemia cell survival and growth.
3. The Phosphoinositide 3-Kinase (PI3K)-Akt-Mammalian Target of Rapamycin (mTOR) Pathway
3.1. Function and Signaling of the PI3K-Akt-mTOR Pathway
The PI3K-Akt-mTOR pathway has been extensively studied in normal and malignant cells [46].
The signaling cascade is activated by a wide variety of extracellular stimuli, including receptor tyrosine
kinases, various integrins, B and T cell receptors, and G-protein-coupled receptors (GPCRs). Family
members of PI3K are Serine (Ser)/Threonine (Thr) kinase heterodimers, which can be divided into three
different classes based on their structural characteristics and substrate specificity [47]. Class I enzymes
are separated into class IA and class IB enzymes, both of which are activated by cell surface receptors.
Class IA enzymes can be activated by receptor tyrosine kinases (RTKs), GPCRs, and various oncogenes
such as the small G protein Ras, whereas class 1B enzymes are activated solely by GPCRs (Figure 1).
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Figure 1. Overview of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin
(PI3K-Akt-mTOR) signaling pathway. Following ligation of cell surface receptors (e.g., growth factor
receptors) phosphorylated receptor tyrosine kinases (RTK) recruits scaffolding proteins, which bind to
the regulatory p85 subunit of PI3K. A subsequent activation of the catalytic subunits of PI3K generates
phosphatidylinositol 3,4,5- trisphosphates (PIP3). Phosphoinositide-dependent kinase-1 (PDK1) and Akt
proteins are then recruited to the plasma membrane, inducing the phosphorylation of Akt on Thr308
by PDK1. This is followed by activation of Akt on Ser473 by the mTOR complex 2 (mTORC2); this
second phosphorylation is necessary for complete activation. Akt controls the activation of mTOR
complex 1 (mTORC1) by constraining the GTPase activity of the TSC1/TSC2 complex towards the
Ras-related GTP-binding protein ras homologue enriched in brain (RHEB) that associates to mTORC1 and
phosphorylates mTOR. The mTORC1 induces cap-dependent messenger RNA (mRNA) translation by
phosphorylating 4EBP1, leading to the formation of eIF4F and the inhibition of autophagy. Both mTORC1
and PDK1 can directly activate S6K1, which in turn activates S6, and hence facilitates protein synthesis and
cell growth. Positive regulation (activation/stimulation) of the pathways is presented as black arrows, and
negative regulation (inhibition) of the pathways is presented as red blunt-ended lines. The abbreviations
shown in the figure can be found in the list of abbreviations.
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Class IA PI3K enzymes include a catalytic (p110) and a regulatory subunit (p85 or p101) [48,49].
In response to extracellular stimuli, recruitment scaffolding proteins, such as the growth factor
receptor-bound protein 2 (GRB2)-associated binding protein 2 (GAB2) or insulin receptor substrates
(IRS) 1/2, bind to the regulatory p85 subunit of PI3K. Sequentially, the catalytic subunits of PI3K are
activated, and phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) generates the second
messenger phosphatidylinositol 3,4,5- trisphosphates (PIP3) [50]. This facilitates the recruitment
of proteins that contain pleckstrin-homology (PH) domains, including the Ser/Thr kinase Akt (also
known as protein kinase B) and its upstream activator 3-phosphoinositide-dependent kinase-1 (PDK1)
(Figure 1).
Akt can function as a proto-oncogene, and there are three structurally active forms of Akt in
mammalian cells termed Akt1, Akt2, and Akt3 or PKB α, β, γ, respectively [51]. All three isoforms
comprise an N-terminal PH domain, a T-loop region of the catalytic domain containing a Thr308
phosphorylation site, and a C-terminal regulatory tail with a Ser473 phosphorylation site [51,52].
Whereas Akt is cytosolic in unstimulated cells, an activation mediated by PI3K requires translocation
of Akt to the membrane, where PIP3 serves as an anchor [53]. At the plasma membrane, PDK1
phosphorylates Akt at Thr308, leading to its partial activation. A subsequent phosphorylation at Ser473
is required for full enzymatic activation. This phosphorylation is achieved by the mTOR complex 2
(mTORC2) as well as by members of the PI3K-related kinase (PIKK) family [51,52]. Phosphorylation of
homologous residues in Akt2 and Akt3 occurs in the same way. This activation leads to the relocation
of Akt to the cytosol or the nucleus, and it has been postulated that Akt then can phosphorylate
more than 9000 downstream substrates [54], thereby regulating important cellular processes such as
cell metabolism, proliferation, transcription, and survival. The mTOR complex 1 (mTORC1) is an
important downstream target of Akt (Figure 1).
The Ser/Thr protein kinase mTOR was first identified in the budding yeast Saccharomyces cerevisiae
during a trial for resistance to the immunosuppressant drug rapamycin [55]. It belongs to the
PIKK family and has a C-terminal catalytic domain with sequence homology to PI3Ks. It is a large,
multi-domain protein with protein kinase activity, adding phosphate groups to Ser or Thr residues
in a wide range of substrates, many of which are involved in anabolic pathways [56]. Insulin and
insulin growth factors (IGFs) [57], nutrients such as amino acids [58], various forms of stress, and the
accessibility of ATP are the main regulators of mTOR.
The activity of mTOR is accomplished by the two separate multi-protein complexes, mTORC1 and
mTORC2. The two complexes differ in their protein components, substrate specificity, and regulation,
and they have dissimilar responses to rapamycin and its derivatives (rapalogs). The mTORC1 is
composed of five units: (i) mTOR, (ii) regulatory-associated protein of mTOR (Raptor), (iii) mammalian
lethal with SEC13 protein (mLST), (iv) DEP domain-containing mTOR-interacting protein (Deptor),
(V) and the proline-rich Akt substrate of 40 kDa (Pras40) [59] (Figure 1). Both Deptor and Pras40
function as inhibitors. The mTORC2 is composed of mTOR, mLST8, Deptor, the rapamycin insensitive
companion of mTOR (Rictor), the mammalian stress-activated protein kinase-interacting protein 1
(mSIN1), and Protor [57,60] (Figure 1).
Raptor is responsible for the phosphorylation of downstream substrates, and this action is blocked
by rapamycin. As mTORC2 contains Rictor rather than Raptor, it phosphorylates a different set
of substrates, although the regulation of mTORC2 activity remains poorly understood. The mTOR
complexes have different upstream mechanisms of activation as well as different downstream substrates.
The main downstream targets of mTORC1 are the ribosomal protein S6 kinase (S6K) and eukaryotic
initiation factor-4E (eIF4E) -binding protein 1 (4EBP1), while most common substrates of mTORC2 are
Akt and related kinases [61]. The S6K protein plays a central yet moderately defined role in cellular
and organismal physiology. There are two identified isoforms of S6K, termed p70 and p85, produced
by differential splicing from a common gene. Both isoforms are implicated in regulation of cell growth,
but the p70S6K isoform has been given the most attention, and the function of the p85S6K remains
poorly characterized. Downstream targets of mTORC1 play critical roles in the regulation of translation.
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The translation initiation complex eIF4F is a heterotrimeric protein complex composed of eIF4E, eIF4A,
and eIF4G [61]. The eIF4E binds to the messenger RNA (mRNA) 5’-cap structure to promote the
initiation of translation. In the unphosphorylated state, 4EBP1 binds to eIF4E, hindering its association
with the complex, and blocking it from binding to mRNA. However, in response to stimuli such as
growth factors, mitogens, and amino acids, mTORC1 phosphorylates 4EBP1s, causing it to lose its
inhibitory effect. This allows the formation of the eIF4F complex and the subsequent initiation of
translation [61]. Furthermore, PDK1 can directly phosphorylate S6K, leading to direct activation of
this key regulator of metabolism [62].
The FK506-binding protein 38 (FKBP38) is a unique member of the FKBP-family, and acts as an
upstream regulator of the PI3K-Akt-mTOR pathway [63]. FKBP38 was identified as an endogenous
inhibitor of mTORC1 that binds to the FKBP-C domain of mTOR. This binding interferes with mTOR
function in a manner comparable to the FKBP12-rapamycin complex [63]. Under conditions rich in
growth factors and nutrients, the FKBP-C domain might interact with Ras homologue enriched in
brain (RHEB)-GTP, releasing mTOR from FKBP38 and activating downstream mTOR signaling [63,64].
A negative feedback loop can be formed in the PI3K-Akt-mTOR pathway by activation of mTORC1.
Phosphorylated S6K will sequentially phosphorylate IRS proteins, triggering their proteasomal
degradation and inhibiting insulin/IGF-1-mediated PI3K activation [65].
The phosphate and homologue protein deleted on chromosome 10 (PTEN) protein and Src
Homology 2 (SH2) domain-containing inositol 5-phosphatases (SHIP1 and SHIP2) directly antagonize
PI3K by dephosphorylating PIP3 back to PIP2; hence, negatively controlling the PI3K-Akt-mTOR
pathway [47] (Figure 1). PTEN is the third most commonly mutated gene in human cancers, underlining
its functional significance [66,67]. The activity of mTOR is also negatively controlled through the
tuberous sclerosis complex (TSC: comprising TSC1 and TSC2). Upon activation, Akt will phosphorylate
and inhibit heterodimeric TSC, which then acts as a GTPase-activating protein (GAP) for small GTPase
RHEB [68]. This activation leads to hydrolysis of bound GTP with subsequent RHEB inhibition.
The inactivation of TSC2 maintains RHEB in its GTP-bound state, thereby supporting augmented
activation of mTOR [68].
The mTORC1 can also be regulated by cellular stress and energy status through TSC, in addition
to growth factors. Moreover, a low energy status can activate AMP-activated protein kinase (AMPK),
which in turn phosphorylates Raptor and TSC2, leading to the inhibition of mTORC1 [68,69]. Amino
acids regulate mTORC1 in a TSC-independent pathway. Thus, multiple stimuli modulate mTORC1 to
control cell growth and autophagy.
3.2. The Role of the PI3K-Akt-mTOR Pathway in Modulating Metabolism
Several extracellular stimuli such as insulin and a variety of growth factors are implicated in the
PI3K-Akt-mTOR pathway activity [70]. Cell proliferation requires energy, and the PI3K-Akt-mTOR
pathway contributes to the regulation of cellular metabolism by several mechanisms [71,72].
Regulation of cellular metabolism by mTOR is complex, as it involves activation of mTORC1 by Akt
and upregulation of hypoxia-inducible factor-1 (HIF1), for the promotion of glycolysis by converting
pyruvate to ATP molecules and lactate [73]. During physiological oxygen levels, HIF1 is deregulated,
but the protein accumulates by increased signaling of mTORC1 and the downstream mediators, 4EBP1
and eIF4E [74]. Furthermore, by promoting translation of nucleus-encoded mitochondria-related
mRNAs, mTORC1 can regulate mitochondrial function and oxidative metabolism [38]. mTORC1
also responds to intracellular and environmental stresses, such as low ATP levels, hypoxia, or DNA
damage, and participates in regulation of cell growth and metabolism by inducing a shift in glucose
metabolism from oxidative phosphorylation to glycolysis [38]. Activation of mTORC1 is reliant on
growth factors and amino acids, such as glutamine, leucine, and arginine; this facilitates feedback
mechanisms for increased uptake of nutrients to act as fuel for anabolic reactions. However, the activity
of mTORC1 is reduced upon starvation [38], and during conditions of high-energy stress, the metabolic
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regulator AMPK is activated. AMPK represses mTORC1 activity indirectly through phosphorylation
and activation of TSC2, and directly through the phosphorylation of Raptor [38].
Interestingly, besides promoting the expression of the enzymes of lipid synthesis and the pentose
phosphate pathway, mTORC1 has also been shown to increase expression of the glucose transporter 1
(GLUT1) and other enzymes of glycolysis [74]. Activated mTORC1 also participates in regulation of
autophagy and mRNA translation. For example, Poulain and coworkers demonstrated the constitutive
activation of mTORC1 in AML cells; hence, indicating the dependence of glucose metabolism in the
malignant cells [75]. This implements mTORC1 as one of many contributors to the glycolytic switch
found in most cancer cells.
3.3. PI3K-Akt-mTOR Signaling in AML
The PI3K-Akt-mTOR pathway is upregulated in AML cells, potentially contributing to metabolic
reprogramming, e.g., constitutively active mutant Akt seems to display increased glycolysis [76].
Thus, as a regulator of glucose metabolism, Akt causes upregulation of the glycolysis phenotype.
However, no correlation between this increased glycolysis and oxygen consumption rates was observed,
suggesting that Akt hyperactivation promotes aerobic glycolysis [76]. In addition, Akt interacts with
PDK1, influencing the entrance of pyruvate into the mitochondrial metabolism [77]. Akt may
also affect oxidative phosphorylation; it was shown that Akt could promote an indirect oxidative
phosphorylation through elevated levels of substrates essential to activity of the TCA cycle and
oxidative phosphorylation, such as pyruvate, ADP, and NADH [78].
Dysregulation of the PI3K-Akt-mTOR signaling pathway subsequent to oncogene activating
mutations, oncogene amplification, upstream activation of RTKs, or inactivation of tumor
suppressor genes has been demonstrated in many human malignancies, including AML [79,80].
The PI3K-Akt-mTOR pathway is central for hematopoietic cells, and regulates crucial functions such
as proliferation, differentiation, and survival. This pathway seems to be constitutively activated in 60%
of AML patients, and this activation seems to be associated with decreased overall survival [79–83].
Mutations in membrane bound-proteins, such as RTKs or GTPases, are major causes of dysregulated
PI3K-Akt-mTOR signaling and are observed in 55% of AML cases [13,66]. However, no available data
indicate that PI3K-Akt-mTOR activity is related to specific etiology of the disease, i.e., de novo, secondary
or refractory/relapsed AML, nor to specific molecular subtypes, i.e., nucleophosmin 1 (NPM1) or fms
like tyrosine kinase 3 (FLT3) mutations or other cytogenetic or molecular genetic alterations [84–86].
Signaling initiated through FLT3 is one of the most important causes of the dysregulation of
PI3K-Akt-mTOR signaling in AML, and FLT3 gene mutations lead to abnormal activation of the
pathway [87,88]. Mutations in the FLT3 gene are among the most frequent mutations seen in AML [89].
These mutations can be classified as internal tandem duplications (FLT3-ITD) or mutations in the
tyrosine kinase domain (FLT3-TKD), with the former being more common in AML [90]. Because
FLT3-ITDs are located in or near the juxtamembrane domain of the RTK, they affect multiple processes
within the activation loop of the TKD, while other mutations are effectively isolated, resulting in the
substitution of single amino acids in the loop [90].
The three classes of PI3Ks (Class I-III) have different structure, cellular distribution, mechanism
of action, and preference of substrates [91]. Expression of the regulatory p85α subunit of PI3K
Class IA was examined in a previous study, which included 40 AML patients, in which 21 patients
(53%) demonstrated increased PI3K activation, and PI3K expression correlated with the AML cells
proliferation capacity [92]. The catalytic subunits termed p110α, p110β, p110γ, and p110δ are
responsible for activation of Akt, and p110δ is the only form that constantly shows elevated expression
in human AML [49,93].
For most, although not all AML patients, constitutive Akt phosphorylation results from the
constitutive activation of the PI3K-Akt-mTOR pathway, which is essential for the survival of AML
cells [82,94]. Furthermore, phosphorylation at Thr308 by PDK1 and at Ser473 by mTORC2 constitutively
activates Akt, an observation detected among the majority of AML patients [82,95]. Akt phosphorylation
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at these two sites has been associated with decreased overall survival in several studies [46,82,96], though
independently, increased PI3K-Akt activity may constitute a favorable prognostic factor in AML [95].
Finally, aberrant AML cell activation of mTORC1, causing the phosphorylation of downstream targets
such as p70S6K, S6RP, and 4EBP1, has also been detected for a large majority of patients [97], but this
activation of mTORC1 may not depend on PI3K-Akt activity alone in human AML [98]. The constitutive
activation of Akt in AML is supported by autocrine IGF-1/IGF-1R signaling and inhibition of IGF-1R
results in decreased activation of Akt for most patients with such autocrine signaling [99].
3.4. Crosstalk between PI3K-Akt-mTOR Pathway and other Signaling Pathways
Crosstalk between PI3K-Akt-mTOR and other signaling pathways is also important, and among
these other pathways, two seem central, namely the Ras-Raf- mitogen-activated protein kinase (MEK) -
Ras- extracellular signal-regulated kinase (ERK) and the spleen tyrosine kinase (SYK) pathway.
The Ras-Raf-MEK-ERK pathway strongly cooperates with the PI3K-Akt-mTOR signaling pathway,
exhibit positive and negative regulation of each other, and together regulate several central cellular
functions [100,101]. Many mechanisms and methods of crosstalk between the two pathways have
been identified, including cross-inhibition, cross-activation, negative feedback loops, and pathway
convergence on substrates (Figure 2).
Binding of an extracellular mitogen to cell surface receptors activates the Ras-Raf-MEK-ERK
pathway [101], and activation of the downstream pathway culminates in transcription factors and gene
expression stimulation [102]. The Ras-Raf-MEK-ERK- PI3K-Akt-mTOR signaling crosstalk is mediated
by three main factors: (i) PI3K, (ii) TSC2, and (iii) mTORC1. Activated, Ras-GTP can directly bind and
allosterically activate PI3K [103–105]. High activation of the Ras-Raf-MEK-ERK pathway can recruit
mTORC1 indirectly through ERK and RSK signaling mediated by the TSC complex [100,106]. The ERK
and RSK sites function to promote mTORC1 activity and tumorigenesis, but they are different from
those phosphorylated by Akt [100], in that they induce a PI3K-independent mTORC1 phosphorylation
of 4EBP1 [100,107,108]. Downstream targets hence involve the Forkhead box O (FOXO) and c-Myc
transcription factors, B-cell lymphoma (BCL) 2-associated agonist of cell death (BAD), glycogen synthase
kinase 3 (GSK3) and phosphofructokinase-2 (PFK2) (Figure 2). Components of the Ras-Raf-MEK-ERK
pathway also exhibit positive regulation of the PI3K-Akt-mTOR pathway. This is mediated by TSC2
and mTORC1 as key integration sites, as they are both affected by PI3K signaling.
Central intracellular pathways involved in downstream activation of the SYK, also involve the
PI3K-Akt-mTOR pathway [109,110]. Chemokine-mediated leukemia support of SYK-dependent
modulation of PI3K-Akt-mTOR signaling has been described to be operative in AML [111].
Overexpression of SYK leads to increased activation of mTOR and Ras-Raf-MEK-ERK signaling
in AML [109]. This seems to be of special interest in AML patients with mutated FLT3 and highly
activated SYK (112). In an active and phosphorylated state, FLT3 associates with SYK through its
C-terminal SH2 domain, and this association increases the activity of FLT3 through phosphorylation.
This cooperative activation of FLT3 and SYK results in an increase in the expression of c-Myc and the
target genes of c-Myc [112]. The importance of crosstalk between SYK and PI3K-Akt-mTOR signaling
is further supported by the observation that inhibition of PI3K-Akt-mTOR pathway activity enhances
the effects of SYK inhibition on AML cell differentiation and viability [112,113]. Subsequent to an
activation of the receptor complex Src, an active Src phosphorylates SYK at tyrosine residues, leading to
its activation [114]. While active, SYK phosphorylates p110/p85 subunits of PI3K, and hence increasing
its catalytic activity, which converts PIP2 to PIP3 [114]. Chemical inhibition of SYK has been tested in
multiple cells lines and results in a dose-dependent inhibition of mTOR [109]. Furthermore, in some
AML cell lines and primary cells, both p70S6K and 4EBP1/eIF4E signaling pathways are influenced
by manipulations in SYK activity, and combined chemical inhibition of SYK and eIF4E has shown a
synergistic effect on AML viability in multiple AML cell lines [109]. This is supported by inhibition of
eIF4E through SYK knockdown, indicating that there are enhanced inhibitory effects of SYK on cell
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viability. Inhibition of eIF4E enhanced AML differentiation when combined with SYK inhibition using
either chemical or SYK-directed short hairpin RNA [109].
Figure 2. Main components and crosstalk between the Ras-Raf-mitogen-activated protein kinase-Ras-
extracellular signal-regulated kinase (Ras-Raf-MEK-ERK) pathway, the spleen tyrosine kinase (SYK)
pathway and the PI3K-Akt-mTOR pathway. All pathways respond to extracellular and intracellular
signals to control cell survival, proliferation, motility, and metabolism, and are activated by the binding
of a growth factor to a receptor tyrosine kinase (RTK) or integrins to receptors. In the Ras-MAPK
pathway, this binding produces binding sites for the SHC and GRB2 adaptor molecules that recruit
SOS to the membrane. SOS catalyzes the exchange of Ras GDP to Ras GTP, followed by the recruitment
and activation of Raf. Protein kinase C (PKC) is directly bound and activated by phorbol 12-myristate
13-acetate (PMA) through its mimicking of the natural ligand of PKC. The mechanism by which
PKC activates ERK remains unclear. Following a Ras activation of MEK, ERK is activated through
an activation loop phosphorylation. The pathway is further regulated by a negative feedback loop
from ERK. Pathway crosstalk is regulated through cross-inhibition and cross-activation between the
components of the Ras-Raf-MEK-ERK and PI3K-Akt-mTOR pathways. Pathway crosstalk can also be
regulated by binding of the p85 subunit of PI3K by phosphorylated SYK. When active, SYK increases
the catalytic activity of PI3K, resulting in conversion of phosphatidylinositol 4,5-bisphosphate (PIP2) to
PIP3. PI3K-Akt and Ras-Raf-MEK-ERK signaling networks exhibit examples of crosstalk between
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intracellular signaling proteins. Positive regulation (activation/stimulation) of the pathways is presented
as black arrows, and negative regulation (inhibition) of the pathways is presented as red blunt-ended
lines. PI3K and Ras-Raf-MEK-ERK signaling meet on mTORC1, which is the master controller of
protein translation. PTEN acts as a strong negative regulator of both pathways. Akt can cross-react
with among others the Forkhead box O (FOXO), B-cell lymphoma (BCL) 2-associated agonist of cell
death (BAD), glycogen synthase kinase 3 (GSK3) and phosphofructokinase-2 (PFK2). The abbreviations
shown in the figure can be found in the list of abbreviations.
4. Inhibition of the PI3K-Akt-mTOR Pathway in AML
It is commonly accepted that a disparity in the regulation of protein kinases may be one of
the primary causes of genetic-based human diseases, and a major part of new drug development
over the last decades has been dedicated to the development of protein kinase inhibitors [115]. The
PI3K-Akt-mTOR pathway has emerged as a possible therapeutic target in human malignancies, and
several pharmacological inhibitors have been developed, including isoform-selective or pan-class I
PI3K inhibitors, Akt inhibitors, rapamycin, and rapalogs as well as dual PI3K-mTOR inhibitors [116].
The rapalogs everolimus and temsirolimus represent allosteric inhibitors directed towards mTORC1
and are now in clinical use. Studies have shown that PI3K positively controls the phosphorylation
of Bad and FOXO3A (Figure 2), two targets downstream of Akt that control cell survival, although,
specific inhibition of PI3K does not induce significant apoptosis in primary AML cells [117].
The efficiency of several selective inhibitors towards the PI3K-Akt-mTOR pathway has been studied
in AML cell lines and primary AML cells, and results have shown that Akt can be reactivated through
negative feedback mechanisms subsequent to rapamycin-mediated mTOR inhibition. Inhibitors
targeting the catalytic domain of mTOR have also been developed [118], and pre-clinical studies of
rapamycin combined with rapalogs targeted at mTOR showed inhibition of clonogenic AML cell
proliferation without inhibition of normal CD34+ cells [97]. The antileukemic effects were further
enhanced by combination with conventional cytotoxic drugs [119]. However, the relevant antileukemic
activity of rapamycin and rapalogs has not been demonstrated in clinical trials [120–125].
Both PI3K and mTOR are members of the PIKK superfamily and share structural domains, and
some inhibitors therefore act on both kinases. An important consequence of inhibiting mTORC1/S6K
by rapalogs has been the increased phosphorylation of Akt [118,126]; this has been observed in both
experimental and clinical studies. Dual inhibition of PI3K and mTOR blocks both the upstream
and downstream pathways of Akt, consequently circumventing activation of Akt subsequent to
the reduced mTORC1-S6K-IRS1 mediated negative feedback loop [127]. Possible reasons for the
failure to demonstrate clinically relevant antileukemic effects by pathway inhibitors include limited
activity in human patients [128], intrinsic molecular defects [129], and dose-limiting toxic effects [130].
Akt is important for a wide range of cellular functions and interacts with an immense number of
substrates [52]. Only a few Akt inhibitors have been developed, and they have not produced convincing
effects in AML [131,132]. Results from selected representative and relatively large clinical studies
of PI3K-Akt-mTOR inhibitors were recently reviewed by Herscbein and Liesveld [133], and Table 1
represents the most relevant studies. These clinical studies justify the conclusions that (i) pathway
inhibitors used alone have only modest antileukemic effects; (ii) pathway inhibition in combination
with intensive chemotherapy have acceptable toxicity; (iii) the doses used in clinical studies can alter
the activation of pathway mediators; and (iv) the most important toxicities revealed by clinical studies
are hematological and gastrointestinal toxicity. However, while there is some evidence it may be more
effective in certain subsets of patients, clinical experience with mTOR inhibition is extremely limited
and has not produced convincing results.
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Table 1. Important clinical studies with mTOR inhibitors. The table summarizes the most important findings in larger studies (>20 patients included) using mTOR
inhibitors either alone or in combination with other chemotherapy regimens for AML patients. The abbreviations shown in the table can be found in the list
of abbreviations.





Ridaforolimus (also known as
AP23573, MK-8669, or
Deforolimus)
55 patients, 23 patients
with AML and three with
other myeloid
malignancies
Ridaforolimus 12.5 mg intravenous
infusion for 5 days every 2 weeks
No complete remissions (CR) or
partial remissions ( PR) Stable disease






Sirolimus (also known as
Rapamycin)
29 patients with refractory
or relapsed AML
Sirolimus in a 12 mg loading dose on
day 1 followed by 4 mg/d on days 2 to
7, in parallel with chemotherapy.




Park et al. [124] Everolimus (also known asRAD001)
28 AML patients below 65
years of age in first
relapse.
Everolimus in increasing doses from 10
to 70 mg, administrated orally on days
1 and 7 in combination with
conventional 3 + 7 daunorubicin +
cytarabine induction therapy.
CR in 68% of patients. Subsequent
intensification with allogeneic stem
cell transplantation in 29% of patients
Gastrointestinal
Respiratory
Amadori et al. [125] Temsirolimus (also known asCCI-779)
53 patients with primary
refractory or first relapse
AML
Clofarabine 20 mg/m2 on days 1–5 and
temsirolimus 25 mg on days 1, 8, and 15
If CR or CRi- monthly temsirolimus
maintenance therapy
CR in 8% of patients
CRi in 13% of patients
Median DFS 3.5 months. Median OS
4 months (9.1 months for responders)
Infectious complications Febrile
neutropenia Transaminitis
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5. Conclusions and Further Perspective
AML patients harbor leukemia cells that display heterogeneous constitutive PI3K-Akt-mTOR
activation profiles [79,95]. These dissimilarities are part of more complex phenotypic variations,
including transcriptional regulation, cross signaling, and cell communication and may be influenced by
growth factor stimulation or various inhibitors of pathway activation [70,79,80]. This is probably again
reflected in the heterogeneity between leukemic cells with regard to energy metabolism, amino acid
metabolism and arachidonic acid metabolism, supported by the finding that modulation of arachidonic
acid metabolism alters the activation of mTOR and its downstream mediators [80]. The activation
status of the PI3K-Akt-mTOR pathway is probably also reflected in clonal heterogeneity and different
gene expression profiles [79]. The PI3K-Akt-mTOR pathway is important for disease development and
chemosensitivity, and activation of this pathway has prognostic impact in AML [79,95]. However, the
results from the initial clinical studies using PI3K/mTOR inhibitors are regarded as disappointing by
many clinicians [100], one should however keep in mind that results in relapsed/refractory patients may
not be representative of effects in patients treated at the time of first diagnosis. Biological identification
of patient subsets should be evaluated in future clinical studies using this therapeutic strategy. Given
the limited effects of these inhibitors so far in clinical trials, it appears to be more promising to combine
PI3K-Akt-mTOR inhibitors with other pharmacological agents. Several new approaches have emerged
the last years in the treatment of AML [134,135]; many of these have already been established in
treatment or have entered clinical trials. Of special interest in the setting of PI3K-Akt-mTOR signaling
and inhibition, is the entrance of inhibitors of the SYK- and Ras-Raf-MEK-ERK pathways. In Table 2,
we summarize both MEK and SYK inhibitors, as well as the major new drugs that have emerged as
potential agents for AML treatment, and shortly address the potential benefits in combining them
with PI3K-Akt-mTOR inhibitors. Given the critical roles of SYK in multiple cellular functions, the
interest in the identification of SYK inhibitors has seen a sharp increase in patent filings claiming such
compounds [136]. Some of these SYK inhibitors have been investigated in clinical trials including
patients with autoimmune diseases and hematological malignancies [111,117], although several of
the new and more potent inhibitors have so far not been evaluated in clinical trials. An interest in
inhibition of the Ras-Raf-MEK-ERK pathway has also increased the last decade [137], and several
inhibitors entering preclinical and clinical trials have emerged. MEK is probably the target where
development has reached the farthest, and recently a clinical trial with the MEK inhibitor binimetinib
was published [138]. Although the antileukemic effects of this inhibitor in monotherapy seem limited,
this should further encourage investigating Ras-Raf-MEK-ERK in combination therapy, including
inhibitors of the PI3K-Akt-mTOR pathway in AML [137,139].
The numbers of mutant signaling proteins identified in AML are high [9], although are more
likely to reflect activation of a limited number of downstream effector pathways [115]. Targeting
of these unifying pathways hence may represent a more broadly applicable therapeutic strategy,
emphasizing the potential rational for combination therapy in AML [139]. Combined treatment, e.g.,
the combination of different pathway inhibitors (i.e., dual pathway inhibition) and the combination
of pathway inhibitors with other targeted therapies or conventional chemotherapy should therefore
also be considered in clinical AML trials. Although the contributions of nearly all components of the
PI3K-Akt-mTOR pathway is currently described in mechanistic detail, there are issues that need to be
addressed further, such as cooperation of this pathway with other pathways. Thus, further analyses of
the interrelations of this pathway with other signaling mediators, pathways and/or genetic factors are
hence needed.
Furthermore, the AML heterogeneity is also reflected by the different effects of PI3K-Akt-mTOR
inhibition, and as also demonstrated by our research group, the effects of these inhibitors seem to vary
considerably among AML patients [70,79,80,140]. No clear mutational profile or other pathological
process related to the disease, has so far been detected to predict response to treatment, although these
features must be evaluated in larger in vitro and in vivo studies.
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Table 2. Emerging therapeutic interventions in AML and their potential benefits in combination with
PI3K-Akt-mTOR inhibitors. The table summarizes new drugs in AML therapy, and shortly describes
the potential benefits of combining them with PI3K-Akt-mTOR inhibitors. Key references for the new
agents and their use in AML are given in the table.
Targets Potential Agents Potential Advantages in Combination withPI3K-Akt-mTOR Inhibitors Key References
DNA methylation Azacitidine, decitabine
Potential synergism through the increase of Akt suppression
and the promotion of mTOR inhibitor expression such as
PTEN
[141,142]
BCL-2 Venetoclax Potential to inhibit AML cell growth [143]
SYK Fostamatinib As SYK cross-reacts with the PI3K-Akt-mTOR, it may be amore broadly applicable therapeutic strategy [136]
MEK Binimetinib
Inhibition of both Ras-Raf-MEK-ERK and PI3K-Akt-mTOR
pathways and their crosstalk can decrease signaling activity
in both pathways, especially in RAS mutated cases
[138]
CXCR4/CXC12 Plerixafor CXCR4 antagonist can lead to sensitization for bothconventional chemotherapy and signaling cascade inhibitors [144]
FLT3 Midostaurin, gilteritinib
Dual inhibition of FLT3 activation and downstream
intracellular targets may potentially have synergistic effects,
especially in FLT3 mutated cases
[145,146]
CD33 Gemtuzumabozogamicin
Inhibition of extracellular binding and signaling can
potentiate the effect of PI3K-Akt-mTOR inhibition [147]
IDH1 Ivosidenib Potentiates the alterations in metabolism associated withPI3K-Akt-mTOR, especially in IDH1 mutated cases [148]
IDH2 Enasidenib Potentiates the alterations in metabolism associated withPI3K-Akt-mTOR, especially in IDH2 mutated cases [149]
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Abbreviations
4EBP1 eIF4E -binding protein 1
AML acute myeloid leukemia
AMPK AMP-activated protein kinase
APL acute promyelocytic leukemia
BAD BCL2 associated agonist of cell death
BCL2 B-cell lymphoma-2
CR complete remission
CRi complete remission with incomplete recovery
CREB cAMP response element-binding protein
DFS disease free survival
eIF4E eukaryotic initiation factor-4E
ERK extracellular signal-regulated kinase
FKBP38 FK506-binding protein 38
FLT3 fms like tyrosine kinase 3
GAB2 GRB2 associated binding protein
GAP GTPase-activating protein
GLUT1 glucose transporter 1
GPCR G-protein-coupled receptor
GRB2 growth factor receptor-bound protein 2
GSK3 glycogen synthase kinase 3
HSC hematopoietic stem cell
HSPC hematopoietic stem/progenitor cell
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IGF insulin growth factor
IRS insulin receptor substrates
IDH isocitrate dehydrogenase
ITD internal tandem duplication
LSC leukemic stem cell
MEK MAPK ERK kinase
mLST mammalian lethal with SEC13 protein
mSIN1 mammalian stress-activated protein kinase-interacting protein 1
mTOR mammalian target of rapamycin
mTORC1 mTOR complex 1









PIP3 phosphatidylinositol 3,4,5- trisphosphates
PKC protein kinase C
PMA Phorbol 12-myristate 13-acetate
PR partial remission
Pras40 proline-rich Akt substrate of 40 kDa
PTEN protein deleted on chromosome 10
RSK Ribosomal S6 kinase
RHEB Ras homologue enriched in brain (RHEB)
RTK receptor tyrosine kinase
S6K S6 kinase
SH2 Src Homology 2
SHIP1 SH2 domain-containing inositol 5-phosphatases 1
SHIP2 SH2 domain-containing inositol 5-phosphatases 2
SREBF1 sterol regulatory element-binding transcription factor 1
TCA tricarboxylic acid
TKD tyrosine kinase domain
TSC tuberous sclerosis complex
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